{"id":"guselkumab-gus","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":{"setId":"1e6dc9ae-1c4c-42d9-87aa-c315ecc51b56","title":"TREMFYA (GUSELKUMAB) INJECTION TREMFYA (GUSELKUMAB) INJECTION [JANSSEN BIOTECH, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Guselkumab binds to the p19 subunit of IL-23, a key cytokine involved in the differentiation and activation of pathogenic T helper 17 (Th17) cells. By blocking IL-23, the drug suppresses the inflammatory cascade that drives autoimmune and inflammatory skin diseases. This mechanism is distinct from TNF inhibitors and other biologics, offering an alternative pathway for treating IL-23-dependent inflammatory conditions.","oneSentence":"Guselkumab is a monoclonal antibody that selectively inhibits interleukin-23 (IL-23) signaling to reduce inflammatory immune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:30.281Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe plaque psoriasis"},{"name":"Psoriatic arthritis"},{"name":"Crohn's disease"}]},"trialDetails":[{"nctId":"NCT07487311","phase":"","title":"A Prospective Cohort Study Evaluating the Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With Difficult-To-Treat Inflammatory Bowel Disease (IBD)","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-01-07","conditions":"Inflamatory Bowel Disease","enrollment":80},{"nctId":"NCT07310095","phase":"PHASE4","title":"A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)","status":"RECRUITING","sponsor":"Xian-Janssen Pharmaceutical Ltd.","startDate":"2025-12-30","conditions":"Crohn Disease","enrollment":78},{"nctId":"NCT07448402","phase":"","title":"Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease","status":"NOT_YET_RECRUITING","sponsor":"Caja Costarricense de Seguro Social","startDate":"2026-05","conditions":"Psoriasis, Psoriasis Arthritis, Psoriasis (PsO)","enrollment":50},{"nctId":"NCT07444060","phase":"","title":"Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-03-01","conditions":"CD - Crohn's Disease, Stricture; Bowel, IBD - Inflammatory Bowel Disease","enrollment":100},{"nctId":"NCT07430319","phase":"","title":"Real-Life Evaluation of Guselkumab Dosing Interval Adjustments","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2025-10-16","conditions":"Psoriasis","enrollment":100},{"nctId":"NCT06249555","phase":"","title":"VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study","status":"RECRUITING","sponsor":"Alimentiv Inc.","startDate":"2024-03-20","conditions":"Crohn's Disease","enrollment":300},{"nctId":"NCT05669833","phase":"PHASE3","title":"Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2023-07-14","conditions":"Psoriatic Arthritis","enrollment":63},{"nctId":"NCT05004727","phase":"PHASE4","title":"Multi-Center PAMPA Study","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2022-02-16","conditions":"Psoriasis","enrollment":176}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TREMFYA","Tremfya"],"phase":"marketed","status":"active","brandName":"Guselkumab (GUS)","genericName":"Guselkumab (GUS)","companyName":"Second Affiliated Hospital, School of Medicine, Zhejiang University","companyId":"second-affiliated-hospital-school-of-medicine-zhejiang-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Guselkumab is a monoclonal antibody that selectively inhibits interleukin-23 (IL-23) signaling to reduce inflammatory immune responses. Used for Moderate to severe plaque psoriasis, Psoriatic arthritis, Crohn's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}